Six Regional Organisations Sign MoU to Strengthen Asia’s Dengue Response as Cases Rise
Announced at the 9th Asia Dengue Summit in conjunction with ASEAN Dengue Day and the first WHO-recognised World Dengue Day, the MoU establishes a regional framework for knowledge-sharing, advocacy and coordinated dengue action. SINGAPORE, June 15, 2026 /PRNewswire/ -- The Asia Dengue Voice and Action Group (ADVA) and partner organisations from...
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ~29.4-day half-life supporting extended dosing intervals -...
Akeso’s Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer. HER3 is broadly expressed across various...
VARON Encourages Oxygen Users to Enjoy Soccer Season with Confidence at Home and On the Go
NEW YORK, June 14, 2026 /PRNewswire/ -- Soccer season brings excitement, community, and unforgettable moments for millions of fans worldwide. Whether gathering with family to watch a match at home, meeting friends at a local sports bar, or traveling to experience the atmosphere of a live game, oxygen users can still enjoy every moment with proper preparation and...
Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products
Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce HONG KONG, June 15, 2026 /PRNewswire/ -- Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", Stock Code: 01110.HK) announced that Morning Gold Medicine Company Limited ("Morning Gold"), a connected person of the Group, has entered into a memoranda of understanding (the "R&D MOUs") with...
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients SEONGNAM and SEOUL, South Korea, June 15, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical...
Technology Leads Insurance Education: Big Jump SEO Partners with Three Major Insurance Platforms to Enhance VHIS Information Quality with Latest Gemini AI Technology
HONG KONG, June 15, 2026 /PRNewswire/ -- Leading digital marketing and search engine optimization (SEO) expert Big Jump SEO Solutions today announced a strategic partnership with three renowned local insurance education platforms: VHIS101, HKVHIS and MoneyHK101. This collaboration will fully integrate Google's latest Gemini AI technology to optimize and elevate the quality of knowledge-sharing for the Voluntary Health Insurance...
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to...
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial suggests SVR35 may predict overall survival...
Ddrops® Championed Active Childhoods and Healthy Growth at Aqua Champs League Fest 2026 Malaysia
KUALA LUMPUR, Malaysia, June 14, 2026 /PRNewswire/ -- Ddrops®, a Canadian family health and nutritional supplement brand, participated as a supporting sponsor of Aqua Champs League Fest 2026 (ACLF 2026) in Malaysia, reinforcing its commitment to children's healthy growth through active lifestyles, positive family routines and simple daily nutrition. Ddrops® x Aqua Champs League Fest 2026...
